

WRITING YOUR APPLICATION



TOP TIPS

Addresses an important question. The RCT must address a question that is clinically important to the urological community. TUF, BAUS and CHaRT will consider each trial on its merits, but particular attention will be paid to studies which are likely to be of ‘landmark’ status.

Necessary. A proper review of the evidence base (including a formal overview of relevant RCTs) should indicate that an RCT is needed.

Feasible. Many RCTs fail to proceed in line with expectations, in particular failing to recruit and retain the required number of participants. The assumptions behind the study would be critically reviewed, with evidence sought up-front that these assumptions are reasonable. If no such reassurance is possible, then it will be sought from a pilot study or early returns as the study commences. The study should be led by a Chief Investigator with the correct blend of experience and clinical credibility.

Financially viable. CHaRT and the Chief Investigator’s host institution involvement with a study must be appropriately financed. We will work with prospective Chief Investigators to ensure grant applications cover the true cost of engagement in the study (in terms of its expense of staff costs and consumables).

Opportunity for innovation: TUF, BAUS and CHaRT are keen to explore **methodological advances** in RCT design, analysis, conduct and reporting, for example, trials involving novel IT applications, trials in difficult settings, that could raise standards for all trials in urology.